Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PRESS RELEASE - Zymeworks Inc. | ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Rule 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 30, 2018
Zymeworks Inc.
(Exact name of registrant as specified in its charter)
|
British Columbia, Canada
|
001-38068
|
47-2569713
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
|
V6H 3V9
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
(604) 678-1388
|
|
|
|
(Registrant’s telephone number, including area code)
|
||
|
Not Applicable
|
||
|
(Former name of former address, if changed since last report)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
| ITEM 8.01 |
OTHER EVENTS
|
The following information is filed pursuant to Item 8.01, “Other Events.”
On October 30, 2018, Zymeworks Inc. (the “Company”) announced that its abstract describing new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for a plenary session presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland from November 13-16, 2018.
| ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS
|
|
(d)
|
Exhibits
|
||
|
Exhibit No.
|
Description
|
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ZYMEWORKS INC.
|
|||||
|
(Registrant)
|
|||||
|
Date: October 30, 2018
|
By:
|
/s/ Neil Klompas
|
|||
|
Name:
|
Neil Klompas
|
||||
|
Title:
|
Chief Financial Officer
|
||||